Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28164980 | 0.91 | KMT2A (0.45) | KMT2AEPHX2FABP5FABP7CYP1A2 | |
| SCHEMBL7362002 | 0.85 | KMT2A (0.52) | KMT2AEPHX2FABP5FABP7CASP3 | |
| Hydrochloric Acid SCHEMBL7357624 | 0.84 | KMT2A (0.51) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL15132492 | 0.83 | KMT2A (0.54) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL4839280 | 0.83 | KMT2A (0.52) | KMT2AEPHX2FABP5FABP7CYP1A2 | |
| SCHEMBL21661027 | 0.82 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL16094918 | 0.81 | KMT2A (0.46) | KMT2AEPHX2FABP5FABP7CASP3 | |
| SCHEMBL30781736 | 0.80 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CYP1A2 | |
| SCHEMBL47693 | 0.80 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CYP1A2 | |
| SCHEMBL29779340 | 0.80 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PSMA7, PSMA4, IL4 | KMT2A 3191/4885EPHX2 2947/4885FABP5 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.